Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
Thaler, J; Fluckinger, T; Huber, H; Lang, A; Abbrederis, C; Seewann, H; Silly, H; Baldinger, C; Duba, C; Huber, C.
Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside.
LEUK RES. 1993; 17(8): 711-715.
Doi: 10.1016/0145-2126(93)90079-Z
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Sill Heinz
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Patients with Philadelphia (Ph) chromosome-positive chronic myelogenous leukemia (CML) and on interferon (IFN)-alpha-2c treatment for at least two months were entered in the present pilot study. IFN-alpha treatment was maintained identically and cytosine arabinoside (Ara-C) was added at monthly cycles of 10 mg/m2/day for ten days subcutaneously. In the case of a leukocyte nadir above 10 G/l, the Ara-C dose was increased to 20 mg/m2/day for 10 days per month. Ten of the eleven patients entered in this study were evaluable for toxicity and response. They received a total of 87 IFN-alpha/Ara-C cycles (3-14/patient). Five patients received 1-5 cycles with Ara-C dose intensification to 20 mg/m2/day. The following gastrointestinal and hematological toxicities were attributable to Ara-C, as they had not been observed in these patients during the preceding IFN-alpha monotherapy period. Gastrointestinal side effects consisted of nausea grade 1 (n = 5) and diarrhea grade 2 (n = 1). Hematotoxicity was observed in eight patients, grade 1 in five patients and grades 2, 3 and 4 in one of the patients each. Both episodes of grades 3 and 4 toxicity were seen during dose escalation to 20 mg/m2. Small cytogenetic responses (4-14%) were observed in 3 patients and a larger one (50%) in one patient, hematological improvement or stable disease in an additional three patients. These preliminary data suggest that the combination of IFN-alpha and low-dose Ara-C is active in inducing cytogenetic responses in CML patients at an acceptable rate of toxicity and therefore warrant further investigation.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Combined Modality Therapy -
- Cytarabine - adverse effects
- Drug Administration Schedule - adverse effects
- Female - adverse effects
- Humans - adverse effects
- Interferon Type I, Recombinant - adverse effects
- Leukemia, Myeloid, Chronic - therapy
- Leukemia, Myeloid, Philadelphia-Positive - therapy
- Leukocyte Count - therapy
- Male - therapy
- Middle Aged - therapy
- Find related publications in this database (Keywords)
- Chronic Myelogenous Leukemia
- Interferon-Alpha
- Low-Dose ARA-C
- Toxicity
- Cytogenetic Remission